U.S. IT Stock News

GlobalFoundries recently appointed Sam Franklin as Chief Financial Officer, cementing leadership continuity as he moves from Interim CFO into the permanent role with broad responsibility for finance and operations. At the same time, GlobalFoundries is exiting the Nasdaq-100 while securing nearly €495 million in German government aid to expand its Dresden semiconductor facilities and deepen its position in power semiconductors and silicon photonics for AI data centers. Next, we’ll explore how...

Cantor Fitzgerald recently reiterated its Overweight rating on Summit Therapeutics while Barclays upgraded the stock to Equalweight, spotlighting ivonescimab’s planned late-2025 Biologics License Application submission and the pivotal global phase 3 HARMONi-3 lung cancer study expected in 2026. These endorsements underscore how ivonescimab and the HARMONi-3 program have moved to the center of the biotech conversation around late-stage oncology assets. With Summit Therapeutics’ shares...

We wouldn't blame ATI Inc. ( NYSE:ATI ) shareholders if they were a little worried about the fact that Robert...

It is hard to get excited after looking at Comstock Holding Companies' (NASDAQ:CHCI) recent performance, when its stock...

First Financial Corporation ( NASDAQ:THFF ) will increase its dividend on the 15th of January to $0.56, which is 9.8...

Washington Trust Bancorp, Inc. ( NASDAQ:WASH ) has announced that it will pay a dividend of $0.56 per share on the 14th...

Over the past year, many Snap-on Incorporated ( NYSE:SNA ) insiders sold a significant stake in the company which may...

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...

Wondering if Johnson & Johnson is still a buy at around $206 a share, or if the easy gains are already behind it? This breakdown will help you decide whether the current price matches the company’s long term fundamentals. Despite a recent dip of 3.6% over the last week, the stock is still up 1.2% over the past month, 43.3% year to date and 46.4% over the last year, which indicates the market has been steadily re-rating J&J’s prospects. That momentum has been shaped by a stream of news, from...

Earlier this week, Coastal Financial, a banking services provider focused on community banking, saw renewed investor interest as robust earnings growth forecasts drew fresh attention from institutional investors. This reaction highlights how confidence from large investors can reinforce market belief in Coastal Financial’s community banking business model and earnings potential. We’ll now examine how this renewed institutional confidence shapes Coastal Financial’s investment narrative and...

Earlier this month, KeyBanc Capital Markets initiated coverage of Kratos Defense & Security Solutions with an Overweight rating, emphasizing its exposure to hypersonics, collaborative combat aircraft drones, and other advanced Pentagon programs alongside recent facility expansions in Vancouver, Jerusalem, and Michigan. This combination of bullish analyst coverage and growing production footprint highlights how Kratos is increasingly aligned with modernization priorities in global defense...

Piper Sandler just kicked off coverage of First Commonwealth Financial (FCF) with an Overweight rating, spotlighting its stronger than peer returns, accelerating earnings, and a valuation that still sits at a discount. See our latest analysis for First Commonwealth Financial. At a share price of $17.26, First Commonwealth’s 1 month share price return of 7.14% contrasts with a softer 90 day share price return, while a 5 year total shareholder return of 87.46% points to durable, if currently...

Photronics (PLAB) has quietly turned into one of those under the radar chip enablers powering the broader semiconductor cycle, and its recent share performance now has investors asking whether the run still has room. See our latest analysis for Photronics. With the share price now at $33.09, Photronics has cooled off a bit after a sharp run, but a 57.12 percent one month share price return and 38.74 percent one year total shareholder return still point to momentum that investors clearly have...

Morgan Stanley recently upgraded Warner Music Group to overweight while several insiders bought shares, coinciding with broad analyst optimism about the company’s prospects. At the same time, Warner Music Group has been cutting costs through layoffs and restructuring, highlighting management’s push to boost efficiency alongside growth initiatives. We’ll now examine how insider share purchases, alongside these restructuring efforts, may influence Warner Music Group’s broader investment...

Earlier this month, Texas Pacific Land Corporation announced a 3-for-1 stock split effective December 23, 2025, alongside a US$505 million cash purchase of 17,306 net royalty acres and 8,147 surface acres to expand its Permian Basin footprint. The company also revealed a partnership with Bolt Data & Energy to develop AI-focused data center campuses on its West Texas land, marking a move to pair its royalty and water assets with digital infrastructure exposure. Next, we’ll examine how Texas...

Texas Roadhouse (TXRH) is back on investors radar after a major brokerage upgrade, with the stock climbing as the firm pointed to easing beef costs ahead and a more appealing post pullback valuation. See our latest analysis for Texas Roadhouse. The upgrade lands after a choppy year for Texas Roadhouse, where a recent pullback set up room for today’s bounce, even as the 90 day share price return of 10.10 percent contrasts with a more muted 1 year total shareholder return of negative 1.07...

CVB Financial (CVBF) has been grinding sideways lately, and that kind of quiet tape can actually be useful for investors because it lets you focus on earnings power, credit quality, and long term valuation. See our latest analysis for CVB Financial. Over the past year the share price has lost some ground, with a negative year to date share price return and a modestly negative one year total shareholder return. This suggests momentum has cooled as investors reassess growth and credit risk...

Planet Labs PBC (PL) has quietly delivered a massive turnaround for shareholders, with the stock up roughly 72% over the past month and almost 59% in the past 3 months. See our latest analysis for Planet Labs PBC. That surge has flipped the script on what had been a tough stretch, with a powerful year to date share price return of 383.12% and a three year total shareholder return of 325.28% signaling that momentum has clearly shifted in Planet Labs PBC's favor. If this kind of swing has you...

ADMA Biologics (ADMA) just lifted its 2025 revenue guidance to $510 million, up from its previous expectation of more than $500 million, a move that puts the company’s growth trajectory squarely in focus. See our latest analysis for ADMA Biologics. The upbeat guidance comes as momentum builds again in the stock, with a roughly 14% 1 month share price return and a standout 3 year total shareholder return above 430% reinforcing the growth narrative. If this kind of biologics growth story has...

UL Solutions (ULS) just delivered a stronger than expected third quarter, with revenue and earnings coming in ahead of forecasts, and that performance is a big part of why the stock has been moving. See our latest analysis for UL Solutions. That backdrop helps explain why, even after a recent 1 month share price return of minus 10.21% and a pullback to 76.95 dollars, UL Solutions still boasts a powerful year to date share price return of 54.98% and a 1 year total shareholder return of 53.20%...

Roku (ROKU) has been back in the spotlight after a wave of bullish analyst calls, with Morgan Stanley and Guggenheim highlighting its connected TV ad momentum and partnership driven platform growth as key upside drivers. See our latest analysis for Roku. The latest analyst upgrades and new content deals, such as adding CNN Headlines and expanding The Roku Channel, have come on top of a 30 day share price return of 16.61% and a year to date share price return of 46.09%. The three year total...

Earlier this month, Legend Biotech reported new long-term clinical and translational data for its CARVYKTI CAR-T therapy in relapsed or refractory multiple myeloma, including updated efficacy and safety findings from the CARTITUDE-1 and CARTITUDE-4 trials. The disclosure that over half of treated patients received the immune-modulating drug tocilizumab, alongside reports of neurologic toxicity with parkinsonism, adds important context to CARVYKTI's real-world risk–benefit profile and...

Marriott Vacations Worldwide (VAC) just doubled down on shareholder returns by lifting its quarterly dividend to 0.80 dollars per share and extending its stock buyback plan through the end of 2026. See our latest analysis for Marriott Vacations Worldwide. Even with this richer dividend and extended buyback signaling management’s confidence, the stock’s 1 month share price return of 13.72 percent comes after a steep year to date share price decline and multi year total shareholder returns that...

Wondering if Palantir is still worth buying after such a huge run, or if the easy money has already been made? You are not alone, and that is exactly what we are going to unpack. Palantir's share price has climbed 5.5% over the last week, 24.9% over the last month, and an eye catching 157.2% year to date, adding to a massive 139.7% gain over the past year and 654.5% over five years. Much of this momentum has been fueled by heightened investor excitement around AI driven analytics and...